Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Discrete Choice Experiment to Assess the Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Patients With Prostate Cancer

NCT06500741 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT06500741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06500741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Discrete Choice Experiment to Assess the Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Patients With Prostate Cancer
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Observational
Overall status
Completed
Start date
November 22, 2024
Completion date
April 2, 2025
Enrollment
374 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer